-60%

est. 2Y upside i

HealthcareSeries B

Osmind is a San Francisco–based public benefit corporation led by scientists, technologists, and psychiatrists to advance new evidence-generating medicine that helps people living with moderate to severe mental health conditions.

Rank

#2289

Sector

Mental Health Software

Est. Liquidity

~4Y

Data Quality

Data: Medium

Osmind presents a moderate upside opportunity for a job seeker, driven by its specialized focus on interventional mental health treatments and a hybrid revenue model that includes both EHR subscriptions and real-world data for research.

Last updated: March 10, 2026

Bull (20%)+195%

Osmind capitalizes on its unique position in interventional mental health, with partnerships like Cybin driving accelerated growth to $64M+ revenue by 2028 and a valuation of $770M as the market for psychedelic and ketamine therapies expands significantly.

Base (50%)+40%

Osmind maintains its strong position in the specialized mental health EHR market, growing revenue to approximately $48.6M by 2028 and achieving a valuation of $365M, reflecting steady adoption and consistent execution.

Bear (30%)-61%

Increased competition from established EHR providers like athenaOne or Tebra entering the specialized mental health space, combined with slower-than-expected adoption of interventional treatments, leads to growth stagnation and a valuation contraction to $100M, significantly impacting common stock value due to liquidation preferences.

Est. time to liquidity~4.0 years

Preference Stack Risk

high

Investors hold $57M in liquidation preferences. In an exit at or below the estimated current valuation of $260M, common shareholders would receive proceeds only after the $57M preference is satisfied.

Dilution Risk

moderate

As a Series B company, Osmind is likely to pursue at least one more funding round (Series C), which will result in further dilution for existing shareholders.

Secondary Liquidity

none

There is no active public secondary market or known tender offers for Osmind's equity at this stage.

Other — 2 roles

View all 2 open roles at Osmind →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Osmind's data — designed to show you've done your homework.

  • 1

    “Given the increasing number of competitors in the mental health EHR space, including newer alternatives like Psychiatry-Cloud and established players like TherapyNotes, how does Osmind plan to maintain its differentiated market position and competitive moat, particularly against those offering broader or more cost-effective solutions?”

  • 2

    “Osmind's revenue model includes both subscription fees for EHR and revenue from life sciences organizations for real-world data. How do you foresee the balance and growth trajectory of these two revenue streams evolving over the next 2-3 years, especially with partnerships like Cybin?”

  • 3

    “With $57M in total funding and the Series B in 2022, what is the company's current thinking on the timeline and potential pathways for a liquidity event, and how does the preference stack impact employee equity value in various exit scenarios?”

Community

Valuation Sentiment

Our model estimates -60% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.